Alclometasone
Explore a selection of our essential drug information below, or:
Identification
- Summary
Alclometasone is a topical corticosteroid used to relieve the symptoms of corticosteroid-responsive dermatoses.
- Generic Name
- Alclometasone
- DrugBank Accession Number
- DB00240
- Background
Alclometasone is synthetic glucocorticoid steroid for topical use in dermatology as anti-inflammatory, antipruritic, antiallergic, antiproliferative and vasoconstrictive agent.
- Type
- Small Molecule
- Groups
- Approved
- Structure
- Weight
- Average: 408.916
Monoisotopic: 408.170351745 - Chemical Formula
- C22H29ClO5
- Synonyms
- (7alpha,11beta,16alpha)-7-chloro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
- 7α-Chloro-16α-methylprednisolone
- Alclometasone
Pharmacology
- Indication
For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Corticosteroid-responsive dermatoses •••••••••••• - Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Alclometasone is a synthetic corticosteroid for topical dermatologic use. The corticosteroids constitute a class of primarily synthetic steroids used topically as anti-inflammatory and antipruritic agents. Alclometasone is a selective glucocorticoid receptor agonist.
- Mechanism of action
The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. Alclometasone initially binds the corticosteroid receptor. This complex migrates to the nucleus where it binds to different glucocorticoid response elements on the DNA. This in turn enhances and represses various genes, especially those involved in inflammatory pathways.
Target Actions Organism ACorticosteroid-binding globulin binderHumans AGlucocorticoid receptor agonistHumans - Absorption
Topical corticosteroids can be absorbed from normal intact skin. Studies have shown that approximately 3% of steroid is absorbed during 8 hours of contact with intact skin of normal volunteers.
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
Hepatic.
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Symptoms of overdose include suppression of adrenal glands, temporary decrease in white blood cell counts, symptoms of hypersensitivity (such as skin rash, hives, itching, and difficulty breathing), and increased susceptibility to infection.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbametapir The serum concentration of Alclometasone can be increased when it is combined with Abametapir. Acarbose The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Acarbose. Acetohexamide The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Acetohexamide. Acetyldigitoxin The risk or severity of adverse effects can be increased when Alclometasone is combined with Acetyldigitoxin. Albiglutide The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Albiglutide. - Food Interactions
- No interactions found.
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Product Ingredients
Ingredient UNII CAS InChI Key Alclometasone dipropionate S56PQL4N1V 66734-13-2 DJHCCTTVDRAMEH-DUUJBDRPSA-N - Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Aclovate Cream 0.5 mg/1g Topical Glaxosmithkline Inc 2006-02-10 2011-02-11 US Aclovate Ointment 0.05 mg/1 Topical Glaxosmithkline Inc 2006-10-11 2007-06-29 US - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Aclovate Ointment 0.5 mg/1g Topical Physicians Total Care, Inc. 2009-10-01 2011-09-30 US Aclovate Cream 0.5 mg/1g Topical PharmaDerm a division of Fougera Pharmaceuticals Inc. 2009-09-01 2015-02-28 US Aclovate Cream 0.5 mg/1g Topical Physicians Total Care, Inc. 2009-09-01 2011-09-30 US Aclovate Ointment 0.5 mg/1g Topical PharmaDerm a division of Fougera Pharmaceuticals Inc. 2009-10-01 2015-02-28 US Alclometasone Dipropionate Cream 0.5 mg/1g Topical E. Fougera & Co. a division of Fougera Pharmaceuticals Inc. 2005-07-12 Not applicable US
Categories
- ATC Codes
- D07AB10 — Alclometasone
- D07AB — Corticosteroids, moderately potent (group II)
- D07A — CORTICOSTEROIDS, PLAIN
- D07 — CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
- D — DERMATOLOGICALS
- Drug Categories
- Adrenal Cortex Hormones
- Anti-Inflammatory Agents
- Corticosteroid Hormone Receptor Agonists
- Corticosteroids
- Corticosteroids, Dermatological Preparations
- Corticosteroids, Moderately Potent (Group II)
- Cytochrome P-450 CYP3A Substrates
- Cytochrome P-450 CYP3A4 Substrates
- Cytochrome P-450 Substrates
- Dermatologicals
- Fused-Ring Compounds
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Immunosuppressive Agents
- Ophthalmologicals
- Pregnadienes
- Pregnadienetriols
- Pregnanes
- Sensory Organs
- Steroids
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Steroids and steroid derivatives
- Sub Class
- Hydroxysteroids
- Direct Parent
- 21-hydroxysteroids
- Alternative Parents
- Gluco/mineralocorticoids, progestogins and derivatives / 20-oxosteroids / 11-beta-hydroxysteroids / 17-hydroxysteroids / 3-oxo delta-1,4-steroids / Halogenated steroids / Delta-1,4-steroids / Tertiary alcohols / Alpha-hydroxy ketones / Secondary alcohols show 7 more
- Substituents
- 11-beta-hydroxysteroid / 11-hydroxysteroid / 17-hydroxysteroid / 20-oxosteroid / 21-hydroxysteroid / 3-oxo-delta-1,4-steroid / 3-oxosteroid / 7-halo-steroid / Alcohol / Aliphatic homopolycyclic compound show 21 more
- Molecular Framework
- Aliphatic homopolycyclic compounds
- External Descriptors
- 11beta-hydroxy steroid, 17alpha-hydroxy steroid, glucocorticoid, 20-oxo steroid, 3-oxo-Delta(1),Delta(4)-steroid, chlorinated steroid, 21-hydroxy steroid (CHEBI:53776)
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 136H45TB7B
- CAS number
- 67452-97-5
- InChI Key
- FJXOGVLKCZQRDN-PHCHRAKRSA-N
- InChI
- InChI=1S/C22H29ClO5/c1-11-6-14-18-15(23)8-12-7-13(25)4-5-20(12,2)19(18)16(26)9-21(14,3)22(11,28)17(27)10-24/h4-5,7,11,14-16,18-19,24,26,28H,6,8-10H2,1-3H3/t11-,14+,15-,16+,18-,19+,20+,21+,22+/m1/s1
- IUPAC Name
- (1R,2R,3aS,3bS,4R,9aR,9bS,10S,11aS)-4-chloro-1,10-dihydroxy-1-(2-hydroxyacetyl)-2,9a,11a-trimethyl-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7-one
- SMILES
- [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])[C@H](Cl)CC2=CC(=O)C=C[C@]12C
References
- General References
- Matoulkova P, Pavek P, Maly J, Vlcek J: Cytochrome P450 enzyme regulation by glucocorticoids and consequences in terms of drug interaction. Expert Opin Drug Metab Toxicol. 2014 Mar;10(3):425-35. doi: 10.1517/17425255.2014.878703. Epub 2014 Jan 23. [Article]
- External Links
- Human Metabolome Database
- HMDB0014385
- KEGG Drug
- D07116
- PubChem Compound
- 5311000
- PubChem Substance
- 46508296
- ChemSpider
- 4470541
- 108088
- ChEBI
- 53776
- ChEMBL
- CHEMBL1201361
- ZINC
- ZINC000030691420
- Therapeutic Targets Database
- DAP000415
- PharmGKB
- PA164747650
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- PDRhealth
- PDRhealth Drug Page
- Wikipedia
- Alclometasone
- FDA label
- Download (191 KB)
- MSDS
- Download (26.3 KB)
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data2 Completed Treatment Allergy Symptoms / Atopic Dermatitis / Pruritus / Psoriasis 1 somestatus stop reason just information to hide 2 Completed Treatment Non-Small Cell Lung Cancer (NSCLC) 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Nycomed us inc
- Altana inc
- Glenmark generics ltd
- Taro pharmaceuticals usa inc
- Glaxosmithkline
- Packagers
- Dispensing Solutions
- E. Fougera and Co.
- Glenmark Generics Ltd.
- Nycomed Inc.
- Pharmaderm
- Physicians Total Care Inc.
- Taro Pharmaceuticals USA
- Dosage Forms
Form Route Strength Cream Topical 0.05 % Cream Topical 0.5 mg/1g Ointment Topical 0.05 mg/1 Ointment Topical 0.5 mg/1g Ointment Topical .5 mg/1g Lotion Topical Cream Topical Ointment Topical Solution Topical Ointment Topical 0.05 % - Prices
Unit description Cost Unit Aclovate 0.05% Ointment 60 gm Tube 141.1USD tube Aclovate 0.05% Cream 60 gm Tube 103.1USD tube Aclovate 0.05% Cream 45 gm Tube 81.19USD tube Aclovate 0.05% Cream 15 gm Tube 54.54USD tube Aclovate 0.05% Ointment 15 gm Tube 52.99USD tube Alclometasone Dipropionate 0.05% Cream 60 gm Tube 52.99USD tube Alclometasone Dipropionate 0.05% Cream 45 gm Tube 41.31USD tube Alclometasone Dipropionate 0.05% Ointment 60 gm Tube 39.27USD tube Alclometasone Dipropionate 0.05% Cream 15 gm Tube 19.81USD tube Alclometasone Dipropionate 0.05% Ointment 15 gm Tube 16.99USD tube Aclovate 0.05% cream 2.91USD g Alclometasone dipro 0.05% crm 1.21USD g DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source water solubility Insoluble Not Available logP 2.7 Not Available - Predicted Properties
Property Value Source Water Solubility 0.137 mg/mL ALOGPS logP 2.11 ALOGPS logP 1.68 Chemaxon logS -3.5 ALOGPS pKa (Strongest Acidic) 12.45 Chemaxon pKa (Strongest Basic) -2.9 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 94.83 Å2 Chemaxon Rotatable Bond Count 2 Chemaxon Refractivity 107.61 m3·mol-1 Chemaxon Polarizability 42.88 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9948 Blood Brain Barrier + 0.9518 Caco-2 permeable + 0.6337 P-glycoprotein substrate Substrate 0.7572 P-glycoprotein inhibitor I Non-inhibitor 0.8049 P-glycoprotein inhibitor II Non-inhibitor 0.8763 Renal organic cation transporter Non-inhibitor 0.8262 CYP450 2C9 substrate Non-substrate 0.8524 CYP450 2D6 substrate Non-substrate 0.9027 CYP450 3A4 substrate Substrate 0.717 CYP450 1A2 substrate Non-inhibitor 0.9228 CYP450 2C9 inhibitor Non-inhibitor 0.9215 CYP450 2D6 inhibitor Non-inhibitor 0.9372 CYP450 2C19 inhibitor Non-inhibitor 0.8962 CYP450 3A4 inhibitor Non-inhibitor 0.7736 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8568 Ames test Non AMES toxic 0.8448 Carcinogenicity Non-carcinogens 0.9132 Biodegradation Not ready biodegradable 0.9974 Rat acute toxicity 2.2398 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9651 hERG inhibition (predictor II) Non-inhibitor 0.6522
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-014i-2924000000-c9d1bae69bf0d5dafed5 Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-00dl-0009200000-f4fa6328c876b5f655bd Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-0006-0009100000-8ec6e75e6d4db9de4133 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-0btc-5009100000-afa66847360939200b19 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-054o-0379100000-651c8b401f66a2b72bfd Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-0a59-0009000000-946573572fc7647fa6ae Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-003l-1962000000-ae5ecb41828c52a470c3 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 196.0451444 predictedDarkChem Lite v0.1.0 [M-H]- 195.34708 predictedDeepCCS 1.0 (2019) [M+H]+ 195.8302444 predictedDarkChem Lite v0.1.0 [M+H]+ 197.24248 predictedDeepCCS 1.0 (2019) [M+Na]+ 194.0126444 predictedDarkChem Lite v0.1.0 [M+Na]+ 203.73917 predictedDeepCCS 1.0 (2019)
Targets
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Binder
- General Function
- Major transport protein for glucocorticoids and progestins in the blood of almost all vertebrate species
- Specific Function
- serine-type endopeptidase inhibitor activity
- Gene Name
- SERPINA6
- Uniprot ID
- P08185
- Uniprot Name
- Corticosteroid-binding globulin
- Molecular Weight
- 45140.49 Da
References
- Zhou Y, Zhang Y, Zhao D, Yu X, Shen X, Zhou Y, Wang S, Qiu Y, Chen Y, Zhu F: TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2024 Jan 5;52(D1):D1465-D1477. doi: 10.1093/nar/gkad751. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Receptor for glucocorticoids (GC) (PubMed:27120390, PubMed:37478846). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors (PubMed:28139699). Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Involved in chromatin remodeling (PubMed:9590696). Plays a role in rapid mRNA degradation by binding to the 5' UTR of target mRNAs and interacting with PNRC2 in a ligand-dependent manner which recruits the RNA helicase UPF1 and the mRNA-decapping enzyme DCP1A, leading to RNA decay (PubMed:25775514). Could act as a coactivator for STAT5-dependent transcription upon growth hormone (GH) stimulation and could reveal an essential role of hepatic GR in the control of body growth (By similarity)
- Specific Function
- core promoter sequence-specific DNA binding
- Gene Name
- NR3C1
- Uniprot ID
- P04150
- Uniprot Name
- Glucocorticoid receptor
- Molecular Weight
- 85658.57 Da
References
- Labeur M, Holsboer F: Molecular mechanisms of glucocorticoid receptor signaling. Medicina (B Aires). 2010;70(5):457-62. [Article]
- Hofmann TG, Hehner SP, Bacher S, Droge W, Schmitz ML: Various glucocorticoids differ in their ability to induce gene expression, apoptosis and to repress NF-kappaB-dependent transcription. FEBS Lett. 1998 Dec 28;441(3):441-6. [Article]
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Substrate
- General Function
- A cytochrome P450 monooxygenase involved in the metabolism of sterols, steroid hormones, retinoids and fatty acids (PubMed:10681376, PubMed:11093772, PubMed:11555828, PubMed:12865317, PubMed:14559847, PubMed:15373842, PubMed:15764715, PubMed:19965576, PubMed:20702771, PubMed:21490593, PubMed:21576599). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase). Catalyzes the hydroxylation of carbon-hydrogen bonds (PubMed:12865317, PubMed:14559847, PubMed:15373842, PubMed:15764715, PubMed:21490593, PubMed:21576599, PubMed:2732228). Exhibits high catalytic activity for the formation of hydroxyestrogens from estrone (E1) and 17beta-estradiol (E2), namely 2-hydroxy E1 and E2, as well as D-ring hydroxylated E1 and E2 at the C-16 position (PubMed:11555828, PubMed:12865317, PubMed:14559847). Plays a role in the metabolism of androgens, particularly in oxidative deactivation of testosterone (PubMed:15373842, PubMed:15764715, PubMed:22773874, PubMed:2732228). Metabolizes testosterone to less biologically active 2beta- and 6beta-hydroxytestosterones (PubMed:15373842, PubMed:15764715, PubMed:2732228). Contributes to the formation of hydroxycholesterols (oxysterols), particularly A-ring hydroxylated cholesterol at the C-4beta position, and side chain hydroxylated cholesterol at the C-25 position, likely contributing to cholesterol degradation and bile acid biosynthesis (PubMed:21576599). Catalyzes bisallylic hydroxylation of polyunsaturated fatty acids (PUFA) (PubMed:9435160). Catalyzes the epoxidation of double bonds of PUFA with a preference for the last double bond (PubMed:19965576). Metabolizes endocannabinoid arachidonoylethanolamide (anandamide) to 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid ethanolamides (EpETrE-EAs), potentially modulating endocannabinoid system signaling (PubMed:20702771). Plays a role in the metabolism of retinoids. Displays high catalytic activity for oxidation of all-trans-retinol to all-trans-retinal, a rate-limiting step for the biosynthesis of all-trans-retinoic acid (atRA) (PubMed:10681376). Further metabolizes atRA toward 4-hydroxyretinoate and may play a role in hepatic atRA clearance (PubMed:11093772). Responsible for oxidative metabolism of xenobiotics. Acts as a 2-exo-monooxygenase for plant lipid 1,8-cineole (eucalyptol) (PubMed:11159812). Metabolizes the majority of the administered drugs. Catalyzes sulfoxidation of the anthelmintics albendazole and fenbendazole (PubMed:10759686). Hydroxylates antimalarial drug quinine (PubMed:8968357). Acts as a 1,4-cineole 2-exo-monooxygenase (PubMed:11695850). Also involved in vitamin D catabolism and calcium homeostasis. Catalyzes the inactivation of the active hormone calcitriol (1-alpha,25-dihydroxyvitamin D(3)) (PubMed:29461981)
- Specific Function
- 1,8-cineole 2-exo-monooxygenase activity
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Vallerand A. and Sanoski C. (2017). David's Canadian Drug Guide for Nurses (16th ed.). FA Davis Company. [ISBN:978-0-803-669468]
Carriers
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Binder
- General Function
- Major transport protein for glucocorticoids and progestins in the blood of almost all vertebrate species
- Specific Function
- serine-type endopeptidase inhibitor activity
- Gene Name
- SERPINA6
- Uniprot ID
- P08185
- Uniprot Name
- Corticosteroid-binding globulin
- Molecular Weight
- 45140.49 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]
Drug created at June 13, 2005 13:24 / Updated at November 01, 2024 03:31